a-1 Antitrypsin (AAT) deficiency is one of the most common genetic diseases in North America, with a carrier frequency of approximately 4% in the US population. Homozygosity for the most common mutation (Glu342Lys, PI*Z) leads to the synthesis of a mutant protein, which accumulates and polymerizes within hepatocytes rather than being efficiently secreted. This lack of secretion causes severe serum deficiency predisposing to chronic lung disease. Twelve to fifteen percent of patients with PI*ZZ also develop liver disease, which can be severe, even in infancy. This is thought to be due to toxic effects of the accumulated mutant Z-AAT within the hepatocyte. Thus, an approach to reduce AAT-deficient liver disease will likely require some mechanism to decrease the amount of Z-AAT within hepatocytes. In this report, we describe studies of small-interfering RNAs (siRNAs) designed to downregulate endogenous AAT within hepatocytes. Three different siRNA sequences were identified and cloned into a recombinant adeno-associated virus (rAAV) backbone, either singly or as a trifunctional (3X) construct. Each had activity independently, but the levels of AAT expression in cell culture models showed the greatest decrease with the 3X construct, resulting in levels that were five-fold lower than controls. The rAAV-3X-siRNA was then packaged into AAV8 capsids and used in vivo to transduce the livers of human Z-AAT overexpressing transgenic mice. Those studies showed a decrease in total human AAT, a clearing of Z-AAT accumulation by immunohistochemistry, and a decrease in monomer Z-AAT within the liver within 3 weeks after vector injection. The rAAV8-3X-siRNA vector may hold promise as a potential therapy for patients with AAT liver disease.
a-1 Antitrypsin (AAT) deficiency is a highly prevalent disorder in Northern Europeans and North Americans, with a carrier frequency of up to 4%. [1] [2] [3] [4] [5] [6] AAT is normally synthesized as a 52 kDa protein secreted from hepatocytes into the serum, and functioning throughout the body as a potent, multifunctional anti-protease. The most common AAT mutation, (Glu342Lys, PI*Z) causes a well-characterized defect in AAT folding, and a predilection for formation of protein polymers by the loop-sheet insertion mechanism. [7] [8] [9] [10] [11] [12] [13] [14] [15] These properties impede secretion of the Z-AAT protein from hepatocytes. Individuals homozygous for this mutation (designated as PI*ZZ) have severe deficiency predisposing to chronic lung disease. A significant percentage of patients with PI*ZZ (12-15%) also develop liver disease as a result of the accumulated, polymerized protein within liver cells, which can be severe, even in infancy.
Gene therapy strategies for AAT deficiency have mostly focused on gene augmentation as a means to treat AAT lung disease. [16] [17] [18] [19] [20] A variety of different vector approaches have been utilized for this purpose, and AAT expression and secretion can often be accomplished from ectopic sites, such as skeletal muscle. The latter approach is currently under examination in phase I clinical trials. 21, 22 A phase I trial of intramuscular injection of a rAAV2-AAT vector has recently been completed, and a phase I trial of a rAAV1-AAT vector has just been initiated.
There have also been some approaches tested in the past animal models that are designed as therapies for AAT liver disease. Such strategies generally seek to use molecular means to downregulate expression of the endogenous mutant Z-AAT. One example is the use of a recombinant SV40 vector expressing anti-AAT ribozymes within the liver of the human Z-AAT overexpressing transgenic mouse model. 23 Since augmentation of the wild-type M-AAT can occur from ectopic sites, these downregulation methods within the liver do not have to necessarily be allele-specific. However, it may be necessary to downregulate Z-AAT within a high percentage of hepatocytes to achieve the desired effect.
The emergence of newer rAAV serotypes, such as rAAV8, that are very efficient for gene delivery in the liver has opened the opportunity for new vector approaches to downregulation of Z-AAT as a therapy for AAT liver disease. 19, [24] [25] [26] [27] [28] In this report, a number of small-interfering RNA (siRNA) constructs directed against AAT were expressed from rAAV vectors in vitro and in vivo and their ability to decrease the levels of intracellular Z-AAT within the liver was assessed. A tri-functional (3X) construct emerged from these studies as a potential candidate for future studies of gene therapy of AAT liver disease.
METHODS siRNAs Design Strategy
Ambion's (Ambion Inc., 2130 Woodward St Austin, TX, USA) siRNA design tool allowed for selection of possible target areas from the human AAT (SERPINA1) mRNA coding region. This tool is based on the article written by Tuschl et al. [29] [30] [31] Three siRNA sequences were selected (Table 1) and further analyzed for their efficiency against AAT expression. One siRNA (AAT1) targets the 5 0 -end of the coding region. The second siRNA (AAT33) targets the middle, and the third siRNA (AAT55) is specific for the 3 0 -end of the human AAT open reading frame. The sequences of all siRNAs are specific only to the human AAT gene as indicated by a BLAST search. The Ambion's negative control (NC) siRNA was used as a negative control.
siRNA-Expressing Constructs
All siRNAs were cloned into the BamHI and HindIII sites of the Ambion's pSilencer-2 plasmid using the following complementary oligos having BamHI and HindIII sticky ends: AAT1-F: GATCCCGACAGATACATCCCACCATTTCAAGAG AATGGTGGGATGTATCTGTCTTTTTTGGAAA; AAT1-R: AGCTTTTCCAAAAAAGACAGATACATCCCACCATTCTCTT GAAATGGTGGGATGTATCTGTCGG; AAT33-F: GATCCCA GGCAAATGGGAGAGACCCTTCAAGAGAGGGTCTCTCCC ATTTGCCTTTTTTTG; AAT33-R: AGCTTTTCCAAAAAAA GGCAAATGGGAGAGACCCTCTCTTGAAGGGTCTCTCCC ATTTGCCTGGGAAA; AAT55-F: GATCCCGCCTATGATCT GAAGAGCGTTTCAAGAGAACGCTCTTCAGATCATAGGT TTTTTGGAAA; AAT55-R: AGCTTTTCCAAAAAACCTATG ATCTGAAGAGCGTTCTCTTGAAACGCTCTTCAGATCATA GGCGG. The plasmid allows transcription of siRNA as a hairpin by using the U6 RNA polymerase III promoter. Transcripts of siRNA form RNA hairpins that are processed by the DICER enzyme to yield short double-stranded RNA molecules (siRNA). The siRNA expression cassette from the pSilencer-2 was subcloned into the proviral AAV plasmid. Proviral AAV plasmid was used to make recombinant AAV virus expressing siRNA. All three siRNAs against AAT were consolidated into a single AAV expression vector. This allowed a single plasmid to carry all siRNAs and save in the cost of producing AAV virus. Two versions of the AAV siRNA vector exist having neomycin (neo) or green fluorescent protein (GFP) marker under the control of HSV-1 TK promoter.
rAAV8 Packaging and Purification Serotype 2 rAAV and rAAV pseudotyped into capsid from serotype 8 were produced by the Vector Core Laboratory, Powell Gene Therapy Center, University of Florida as described before. 19, 32 Human Cell Lines The HEK-293 cell line (ATCC no. CRL-1573, Manassas, VA, USA) and the HepG2 liver cell line (ATCC no. HB-8065) were used to test siRNA efficacy against AAT expression. HepG2 cell lines constitutively express high levels of AAT. Cells lines were transfected with plasmid expressing siRNA and GFP marker and sorted using FACSort (FACS Vantage 
Portal Vein Injection of rAAV8 Vectors In Z-AAT Transgenic Mice
PiZ-transgenic mice have been described previously. [34] [35] [36] [37] Injection has been described previously. 19 Work is carried out completely under a sterilized laminar flow hood in SPF animal facility. A portable rodent isoflourane machine is used at 3% mixture. The preparation time for the surgery is approximately 1 h. All aseptic rodent surgery guidelines are strictly followed. The mouse is first identified with an ear tag, placed into induction chamber and initially administered 5% isoflourane, which is then dropped down to 2-3% once the proper plane of anesthesia is achieved. A non-steroidal ophthalmic ointment is applied over eyes of mouse to keep moist. The mouse is placed in dorsal recumbancy with the anesthesia mask over its head. A depilatory cream is applied onto the surgical site and is let set for approximately 1-2 min. After completely removing all depilatory substance from the surgical site, it is prepped with iodine and finally wiped away with 70% isopropyl alcohol. The initial incision of the dermal layer is started and after dermal layer is cut, an incision of the visceral layer is performed. Sterile 2 Â 2 0 gauze moistened with 1 Â PBS is placed immediately parallel to the incision. Sterile cotton-tipped applicators (also moistened with 1 Â PBS) are used to gently lift out the intestines onto the sterile gauze. Once the intestines have been successfully moved, the chest is spread. Chest spreaders are placed on each side of the incision to expose the area around the portal vein. Once the chest is exposed, sterile cotton tipped applicators are used to lift up the fatty area under the first lobe of the liver. Under the lobe the portal vein is clearly visible. A 31 g 3/10 ml insulin syringe is used to inject a 100 ml volume of virus/PBS mixture into the portal vein. At this point the needle is at approximately a 101 angle to the vein. The needle is carefully placed into the vein and the plunger on the syringe is depressed to inject the virus. As the needle is pulled out, a cotton tipped applicator is quickly placed over the injection site. Compression of this vein to stop bleeding can sometimes take up to 2-3 min. The applicator is slowly removed from the portal vein and the area is watched closely for any signs of bleeding. If bleeding takes place new applicators are placed over the injection site. Once the bleeding stops, the intestines are placed back into abdominal cavity using applicators moistened with 1 Â PBS. The chest spreaders are removed from the mouse and intestines are re-hydrated with a pipette and 100-200 ml of 1 Â PBS. The visceral layer is sewn with 5-0 Vicryl suture using a simple continuous loop stitch with interrupts of square knots on the ends. The dermal layer is then sewn using 5-0 Ethilon suture. The mouse is then carefully placed in dorsal recumbence inside of a clean cage on top of a heating pad set on low and the animal is then monitored closely until it recovers completely from anesthesia. Post-surgical guidelines are followed according to IACUC policy.
Histology, Histochemistry and Immunohistochemistry on rAAV8-Injected Mice
Histology was performed on organs from all mice harvested at day 14 as a final experimental end point. For determination of histological changes, liver samples were fixed in 10% neutral-buffered formalin (Fisher Scientific), and embedded in paraffin. Sections (5 mm) were stained with hematoxylin and eosin and periodic acid-Schiff (PAS) with or without diatase treatment. Immunohistochemistry was performed using rabbit anti-human AAT (Research Diagnostics Incorporated) or anti-GFP (Abcam) as described previously. 19 
Histological Analysis
For computerized quantification of histochemistry and immunohistochemistry slides, 10 random fields at Â 10 were photographed from the liver sections for each mouse. The pictures where then analyzed using MetaMorph 6.3r7 software. Positive pixels were selectively detected and uniformly displayed with an orange pixel overlay using the threshold function. The threshold area corresponding to positivestained area and was measured with the oregion measurement4 function.
Monomer-Polymer AAT Analysis on Liver Extracts
Analysis of Z-AAT protein monomer and polymer content in the liver has been described previously. [38] [39] [40] For soluble/insoluble protein separation (Figure 7a ), 10 mg of whole liver was added to 2 ml buffer at 41C (50 mmol/l Tris-HCl (pH 8.0), 150 mmol/l NaCl, 5 mmol/l KCl, 5 mmol/l MgCl 2 , 0.5% Triton X-100 and 80 ml Complete s protease inhibitor stock).
The tissue was homogenized in a prechilled Dounce homogenizer for 30 repetitions, then vortexed vigorously. A 1-ml aliquot was passed through a 28-gauge needle 10 times. The total protein concentration of the sample was determined, and a 5-mg total liver protein sample was aliquoted and centrifuged at 10 000 g for 30 min at 41C. Supernatant (soluble (S) fraction) was immediately removed into fresh tubes; extreme care was taken to avoid disturbing the pellet (insoluble (I) fraction). The insoluble polymers pellet (I fraction) was denatured and solubilized via addition of 10 ml chilled cell lysis buffer (1% Triton X-100, 0.05% deoxycholate, 10 mmol/l EDTA in PBS), vortexed for 30 s, sonicated on ice for 10 min and vortexed. Figure 1c were subjected to In vivo gene silencing of PI*Z by rAAV PE Cruz et al a two-way repeated measures ANOVA (Jandel SigmaStat v2). Data in Figure 3 were compared by repeated measure analysis of eight subjects with four in each group using the Greenhouse-Geisser and was conducted by using PROC GLM in SAS. Greenhouse-Geisser test shows that the time and the interaction between time and treatment are both highly significant (Po0.0001 and P ¼ 0.002).
RESULTS

Downregulation of Z-AAT in Transiently Transfected Cell Lines
The rAAV-siRNA constructs described in Tables 1 and 2 were initially co-transfected into HEK-293 cells with either M-AAT or Z-AAT to examine the efficiency of downregulation. In the case of M-AAT, culture media levels decreased to approximately 40% of baseline with each of the three siRNAs (Figure 1a) . With Z-AAT, the reduction was also to approximately 40% of baseline with the AAT1 siRNA, but was less extensive with either of the two other siRNAs alone (Figure 1b) . However, when all three active siRNAs were combined in a single construct (3X) the effect in transient co-transfection with Z-AAT in the cell line was much greater. The maximal effect, a five-fold reduction, was seen at day 2 post-transfection (Figure 1c ).
Downregulation of Stable Endogenous Human AAT Expression in HepG2 Cells
To determine whether the effects of the rAAV-siRNAs were generalizable to a stably expressed, endogenous AAT allele, we transduced HepG2 cells with a rAAV vector expressing NC-siRNA or the AAT1 siRNA. Despite the fact that these In vivo gene silencing of PI*Z by rAAV PE Cruz et al studies were carried out with a monofunctional construct, human AAT expression was reduced by nearly 50% ( Figure  2a ). Because transduction and transfection efficiency of these cell lines is relatively low, we used a new construct with the GFP reporter gene as well as the siRNA so that cells transfected could be sorted for GFP expression. The GFP-expressing subset was then used to examine downregulation by AAT allele (Figure 2b ). This provided an important indication of a positive effect on target RNA transcribed from a stably expressing, endogenous AAT allele.
In Vivo Downregulation of Human Z-AAT Expression
To determine whether Z-AAT could be reduced in an intact liver, cohorts of Z-AAT transgenic mice were transduced with 1 Â 10 11 vector genomes of the rAAV8-3X-siRNA construct. Measurement of circulating serum levels of human Z-AAT showed a significant reduction (approximately two-to threefold) (Figure 3 ) as compared with levels observed with a control siRNA vector. Repeated measure analysis determined that the time and the interaction between time and treatment are both highly significant (Pr0.0001 and Pr0.002). Further analysis using a two-way ANOVA showed that the difference of the two treatments at day 1 was statistically different (Pr0.0003) from the difference of the two treatments at day 14. This indicates a significant reduction in the PiZ AAT levels at day 14 in the 3X-siRNA group.
Next, we sought to determine whether AAT accumulation would be cleared after hepatic delivery of the rAAV8-3X-siRNA construct. To determine whether the transduction efficiency was equivalent between the active rAAV8-3X-siRNA and the rAAV8-NC-siRNA, immunostaining was performed on transduced livers for neomycin phospho- In vivo gene silencing of PI*Z by rAAV PE Cruz et al transferase, expressed from neo gene cassettes inside both vectors. Fortunately, the neo cassette was small enough to fit inside the packaging capacity of rAAV8 along with the 3X-siRNA-expressing cassette. Immunohistochemistry indicated equivalent staining for transgene expression in both groups of mice (Figure 4) . In contrast, hAAT-Pi*Z protein was detectable in the rAAV8-NC-siRNA, and this intracellular Z-AAT signal was significantly cleared in rAAV8-3X-siRNA ( Figure 5 ). The clearing was somewhat heterogeneic, but overall was markedly different between hAAT-Pi*Z livers treated with the active siRNA construct and the control. Staining for PAS-positive material after diastase digestion was similarly intense in the controlled, and cleared in a patchy distribution in the animals treated with the active 3X-siRNA vector ( Figure 6 ).
Selective Decrease in Monomer vs
Polymer Z-AAT Z-AAT is appropriately transcribed and translated, but when the nascent polypeptide enters the ER lumen it undergoes abnormal folding and very few molecules reach a secretioncompetent conformation. Some of the individual (monomeric) Z-AAT molecules bind together into long, polymeric chains and reside in the ER of the cell in a conformation with a very long biological half-life. To determine whether the effects of the rAAV8-3X-siRNA were on the monomer pool of Z-AAT vs the polymer pool, we analyzed liver samples using a previously published assay. First, the Z-AAT polymers are isolated from the monomers in the liver lysates under non-denaturing conditions and then the separate polymer and monomer fractions are denatured and compared by quantitative immunoblot. The denaturation step reduces the polymers to monomers so the bands can be compared at the same molecular weight. 38, 40 On the basis of the results, there was a marked decrease in hAAT monomer after 2 weeks, while polymer AAT remained relatively stable over this period ( Figure 7 ). This result is consistent with the prediction that rAAV8-3X-siRNA would interrupt the de novo production of Z-AAT and therefore reduce the pool of newly synthesized In vivo gene silencing of PI*Z by rAAV PE Cruz et al monomer, but not affect the previously accumulated and exceedingly stable Z-AAT protein polymer. The ability of this decrease in Z-AAT production to eventually result in a decreased accumulation of polymer Z-AAT over a long period of time was not tested in these experiments.
Serum Chemistry
To determine whether the transduction of the hepatocytes by rAAV8 or the transcription of the siRNA within the hepatocytes induced any hepatocellular toxicity, the serum levels of ALT and AST were measured 14 days after treatment ( Figure 8 ). Both groups of siRNA-treated mice show serum levels within normal range for both enzymes (ALT normal range: 28-184 U/l and AST normal range: 55-255 U/l). Mice treated with 3X-siRNA showed a reduction in the serum levels of both enzymes when compared with control siRNAtreated mice. Only the reduction AST levels were statistically significant (Pr0.05).
DISCUSSION
The results presented here clearly demonstrate the biological activity of anti-AAT siRNAs expressed from an U6 promoter in the context of a rAAV vector construct. The ability to downregulate endogenous M-AAT or Z-AAT was demonstrated in both cell culture models and in vivo after portal vein injection of a rAAV8-pseudotyped version of the trifunctional 3X-siRNA vector. The biological effects included a decrease in the amount of Z-AAT secreted from cells and a decrease in the intracellular accumulation of Z-AAT within the liver of transgenic mice. The latter effect was primarily due to a reduction of monomer forms of the mutant protein. A high percentage of hepatocytes showed immunohistochemical evidence of a decrease in intracellular Z-AAT, which is consistent with earlier studies by a number of groups, indicating that rAAV8-pseudotyped vectors are quite efficient for transduction of murine liver. 19, 28, 41, 42 In fact, the inability of the original rAAV2-based vectors Software, sections for each rAAV8-siRNA transduced livers were analyzed. Thresholded area represents the area on the section that is within the parameters considered to be positive staining. Results are expressed as the mean threshold area for four different livers for each group7s.e.m.
In vivo gene silencing of PI*Z by rAAV PE Cruz et al to transduce stably a high percentage of hepatocytes was a fundamental limitation preventing application of molecular downregulators to Z-AAT-related pathology in the past. 43, 44 The decrease in Z-AAT in both in vitro and in vivo assays suggested that rAAV-3X-siRNA may be potent enough to decrease Z-AAT protein expression to a level similar to or lower than that observed in heterozygous PI*MZ individuals. These individuals do not experience severe AAT liver disease as observed in homozygous PI*ZZ patients. There is some indication that PI*MZ individuals might have an increased risk of chronic liver disease later in life, but the pediatric liver disease typical of PI*ZZ patients is generally not seen. 3 This suggests that clinical benefit might be derived from decreases of Z-AAT of the magnitude observed in this study.
These studies were limited in a number of ways. In vivo studies were relatively short term. This did not allow sufficient time to test the ability of this vector approach to ultimate lead to a decrease in intrahepatic Z-AAT polymers. It also limited the ability to examine any salutary effects that the 3X-siRNA might have on the rather subtle liver pathology present in the Z-AAT transgenic mice. Larger studies in the future with longer time courses will be planned to examine the downstream effects of reduced Z-AAT production and to determine if reductions in Z-AAT polymer accumulation will result. 6 Recent studies by Kay et al 45 suggest that overexpression of siRNA in mouse liver could produce hepatotoxicity, perhaps due to interference with the endogenous microRNA mechanisms operative within these cells. To identify any potential hepatocellular toxicity, two markers of hepatocellular injury were measured in the rAAV8-siRNA-treated mice in our study. The serum levels of ALT and AST were within normal ranges. Thus, there was no evidence of liver toxicity within the first 2 weeks after treatment. Clearly, toxicity questions must be addressed further in additional longer term studies. 
